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Abstract.   
Chronic migraine (CM) is characterized by the International Headache Society classification 
(ICHD-3) as headache that occurs for greater than or equal to 15 days a month, lasting 4 or more 
hours. For chronic migraine patients, the goal with prophylactic treatment is to prevent future 
attacks and reduce the migraine frequency and severity. OnabotulinumtoxinA is the most 
universally accepted medication for the treatment of chronic migraine; and if successful, reduces 
migraine frequency up to 50%.  The goal of CGRP (Calcitonin-gene-related peptide) antagonists 
is to reduce the frequency of chronic migraines by targeting the CGRP protein that is elevated 
during a migraine attack. The aim of this study is to further explore the effectiveness of 
combining CGRP antagonists and Botox for the treatment of chronic migraine. We will analyze 





















              Chronic migraine (CM) is characterized by the International Headache Society 
Classification (ICHD-3) as headache that occurs for greater than or equal to 15 days a month, for 
greater than 3 months, lasting 4 hours or more (Agostoni et al.,2019). The neurologic condition 
is genetically linked and can be highly disabling. Chronic migraine is the most common type of 
daily headache seen by specialists in an outpatient setting. Patients that suffer from CM, typically 
also suffer from other psychiatric and medical conditions. Due to this comorbidity, it is at times 
difficult to diagnose. CM is less common that other types of migraine variants, but it is 
associated with greater disability, interference with everyday activities (i.e. work and school) and 
impacts quality of life. For chronic migraine patients, the goal with prophylactic treatment is to 
prevent future attacks and reducing the migraine frequency and severity. However, there are 
fewer approved therapies than there are for episodic migraine (Aurora et al.,2014) 
 There are multiple orally administered medications that can be used in the treatment of 
CM. These medications include, beta-blockers (propranolol, nadolol, timolol), anticonvulsants 
(topamax, valproate), tricyclic antidepressants (amitriptyline, nortriptyline), antihypertensives 
(candesartan), and calcium channel-blockers (flunarizine). Typically, these medications are used 
when migraine frequency has increased, and patients have failed acute rescue treatment such as 
triptans (sumatriptan, rizatriptan, naratriptan etc.) and other over the counter medications. The 
main objective of prophylactic medications should be to reestablish the ability to function and 
improve the quality of life of those with CM 
Migraine Therapies. 
 Botox (onabotulinumtoxinA) is considered when patients have failed multiple other 
prophylactic preventatives and headache frequency and severity are high. The prophylactic 
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effects were initially observed by a plastic surgeon who treated patients cosmetically for 
wrinkles, and an open-label study involving 106 patients with headaches was conducted (Binder 
et al.,2000) which showed that there was a positive benefit. OnabotulinumtoxinA is one of the 
only prophylactic medications universally used in the treatment of chronic migraine. Botulinum 
toxin is a natural product synthesized by an anaerobic bacterium called Clostridium botulinum. 
The primary action is to block the pre-synaptic release of acetylcholine at the neuromuscular 
junction, which results in temporary paralysis of the muscles. The secondary action involves the 
inhibition of a range of neurotransmitters and inflammatory cells.  For significant benefit, 
onabotulinumtoxinA is injected every 3 months or 12 weeks.  The recommended reconstituted 
dose is between 155 to 195 units per visit. Botox is typically injected to at least 31 injection sites 
across various muscles in the head, face and neck.  
CGRP (calcitonin gene-related peptide) is a protein that acts like a neurotransmitter.  It is 
present on the trigeminal ganglia nerve in the brain. CGRP antagonists are the first migraine-
specific preventive medication group developed. The first of which was approved by the FDA in 
May 2018.The three main medications currently on the market are Aimovig (erenumab-aooe), 
Emgality (galcanezumab-gnlm) and Ajovy (fremanezumab-vfrm). These new medications have 
less side effects - for example, they do not cause vasoconstriction, which is a major limitation in 
the use of triptans (Edvinsson, 2017). They directly treat part of the underlying mechanism of 
migraines. They aim to reduce the frequency and severity of episodic and chronic migraine. 
Although new to the market, CGRP antagonists’ have shown promising results in the treatment 
of CM and EM (episodic migraine) as well. Research has shown that the levels of CGRP 
circulating in the body are elevated in patients with chronic migraine. Anti-CGRP medications 
target the molecules and are associated with lowering the circulating CGRP levels during a 
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migraine attack (Agostini et al.,2019). The antagonists block the inflammatory molecule CGRP, 
and keep it from escalating even further, therefore, reducing the chances of future migraine 
attacks. 
Literature Review 
Melo-Carrillo (2019) looked to explore the effects of Botox injections on the activation 
of meningeal nociceptors by cortical spreading depression (CSD). CSD is associated with 
significant failure of brain ion homeostasis, efflux of excitatory amino acids from nerve cells, 
increased energy metabolism and changes in cerebral blood flow (Lauritzen, 2011). This paper 
was interesting because it looked at the different mechanisms of onabotulinumtoxinA and CGRP 
antagonists and which fibers each one targets. The authors understood that a migraine begins 
with the activation of the nociceptors that supply the meninges. Medications that prevent the 
activation of the nociceptors will be effective in reducing migraine frequency. They examined 
myelinated C- and unmyelinated A&-meningeal nociceptors’ responses in female rats. Melo-
Carrillo (2019), was the first study to find out if the activation of meningeal nociceptor by a 
stimulus that originates in the CSD rather than the outside of the BBB can be attenuated by 
extracranial injections of onabotulinumtoxinA. The study concluded that there is a possibility 
that the mechanism of Botox in preventing headache involves mild but lengthy reduction in the 
firing of the unmyelinated C- fibers but suggested that more research be done on the thinly 
myelinated A&- fibers. They also found that the mechanism of action of Botox differs from that 
of a CGRP antagonist. This is interesting as it informed the current research, that CGRP 
antagonists and Botox can be beneficial in treating chronic migraine. In their clinical study, 
Zhang et al (2016) showed that when Botox is injected directing to the dura, it can inhibit naïve 
C-fiber meningeal nociceptor responses to mechanical nociception, reverse and prevent their 
Running Head: Chronic Migraine Treatment  
 
 6 
sensitization by inflammatory mediators. There is evidence that onabotulinumtoxinA can reduce 
the frequency of migraine into the range seen with episodic migraines (Aurora, 2010). Further 
treatment with CGRP antagonists could reduce the frequency of migraines. Both treatment 
options can be used together as they have different mechanisms and ultimately provide relief for 
the patient. 
Edvinsson and Goadsby (1990) looked for CGRP in patients during a migraine attack, 
taking blood samples from the jugular vein- near the point of release in the brain- instead of the 
arm. The study confirmed the notion that CGRP is released in significant amounts in the body 
during a migraine attack and was the only neuropeptide released during the headache phase. In 
his research study, Edvinsson (2017) looked at the history of the trigeminal pathway, the role of 
CGRP in migraine attacks and the messenger molecules involved. This was interesting because it 
is well known that CGRP plays a role in a number of intracranial brain regions associated with 
chronic migraine. Edvinsson did however, believe that these regions are not the direct targets of 
effective CGRP treatment. He postulated that the targets of CGRP are located outside the brain 
blood barrier. These regions include intracranial and extracranial, dural mast cells, blood vessels 
and other peripheral parts of the trigeminal pathway. The trigeminal ganglion plays a major role 
in primary headache pathophysiology. Multiple studies have found that there are CGRP 
containing nerve fibers within the trigeminal ganglion. Migraines involve the activation of the 
trigeminal system and dilatation of cranial vessels. It is hypothesized that trigeminal-targeted 
preventative treatments counteract the impingement of nociceptive input from highly sensitized 
trigeminal neurons on brain stem second order neurons, thus preventing central sensitization, a 
key pathophysiological mechanism of chronic migraine (Agostoni, 2019).  
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Researchers have hypothesized that recurring migraine episodes and comorbid 
conditions, such as medication overuse or anxiety/depression, may lead to dysfunction of pain 
modulation pathways. This then causes reduced nociceptive thresholds and atypical release of 
nociceptive molecules (Aurora, 1990). Proper brain function requires that all the chemicals are at 
optimal levels, and all nerve pathways are faultless. In the event any of these things are 
interrupted, migraine may occur. Imaging studies have shown activation of regions that contain 
numerous neurons and nerve fibers, multiple neurotransmitters that are connected to synapses 
and receptors. Due to the complexity of this pathway, it is important that it is fully understood. 
Multiple methods of combating the CGRP receptors that are released at a migraine attack could 
prove beneficial.  
 According to a study performed by Masters-Israilov and Robbins (2019), a majority of 
the chronic migraine patients who received onabotulinumtoxinA experienced the phenomenon of 
wear off. This phenomenon is documented by those who experience it approximately 2-4 weeks 
before their next scheduled treatment. The study included 143 patients who have chronic 
migraine and were treated with onabotulinumtoxinA. Their results showed that 62.9% of the 
sample documented wear off (n=90) The researchers indicated that almost two-thirds of the CM 
population who receive onabotulinumtoxinA will experience wear off. These conclusions 
suggest that clinicians should increase the number of units administered to hinder the 
phenomenon from ocurring. Zidan et al, (2019) found that CM patients have reported a period of 
increased headache frequency and severity before their next treatment. Their research study 
found that the response to onabotulinumtoxinA is not uniform and that the current regimen of 
treatment-12 weeks- allows for a period of vulnerability during which migraines attacks can 
occur. The results indicated that most of the participants experienced the start of wear off at week 
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8 of their cycle. According to the researchers, the period of vulnerability can be at the start and 
end of a treatment cycle. The presence of wear off can be identified if there is a quantitative 
increase in the use of abortive medications/therapies or emergency room visits to treat the 
migraines. Bridge therapies such as nerve blocks, intravenous injections, intramuscular ketorolac 
injections (Masters-Israilov & Robbines, 2019) have been used to alleviate migraine attacks. 
CGRP antagonists should also be considered by clinicians as one of the possible bridge therapy 
options as it directly treats part of the underlying mechanism of migraines. It will also prove 
beneficial due to the fact that CGRP antagonists are administered once a month (30 days), 
therefore it will put the wear off phenomenon at bay until the next treatment with 
onabotulinumtoxinA.  
 The aim of this study is to further explore the effectiveness of the combination of CGRP 
antagonists and onabotulinumtoxinA for the treatment of chronic migraine. This study will 
analyze data to confirm or deny that migraine frequency and severity are further reduced with the 
use of a CGRP antagonist medication. Each medication has different mechanisms that target or 
act on different receptors within the brain. Concurrent treatment can prove beneficial and further 
clinical studies should be conducted to further investigate the use of the medications for the 
treatment of chronic migraine. 
Method. 
              This study looked at 24 respondents to a survey sent out to a convenience sample of 
chronic migraine patients attending a headache program. The survey was sent out by the office of 
the Medical Director of the Headache Program. The survey was distributed for 4-6 weeks. Using 
descriptive analysis and visualizations, we used the responses/data collected to investigate, and 
answer if the addition of a CGRP antagonist provided further reduction of migraine frequency.  




 After six weeks of data collection, 24 surveys were completed and returned. The surveys 
were handed out to patients in a Headache Program after their individual Botox procedures. 
Patients were informed that the surveys were anonymous. The survey had 8 questions that we 
estimated would take 2- 4 minutes to complete.  
 
Figure 1. 
The p-value of 0.004, (p < 0.5) indicates that there is strong evidence against the null hypothesis 
and therefore is statistically significant.  
          

























Severity Reduction on Botox
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The images above show that the majority of the sample population have reduction in frequency 






The p-value of 0.683 (p >0.5) indicated that there is statistical significance and thus failing to 
reject the null hypothesis.  Of the 24 responses, n=11 did experience positive benefit and n=13 




















Positive Benefit on a CGRP
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Figure 6.                                                 Figure 7. 
The images above illustrate the percentage of the further reduction of migraine frequency and 
severity on CGRP antagonists.                                                                      
Discussion. 
 
    For several years, there have been very few migraine specific medications on the 
market, leaving patients with limited treatment options for chronic migraine. CGRP antagonists 
recently joined onabotulinumtoxinA as an FDA approved treatment for CM. The goal for chronic 
migraine patients being treated with onabotulinumtoxinA and CGRP antagonists, is to bring 
down the migraine frequency and severity to a level that has them characterized as episodic 
migraine (4-14 days a month).   
           The results were as expected regarding the question of onabotulinumtoxinA wear 
off.  CM patients do experience the wear off phenomenon and therefore will need bridge therapy 
of some kind. Of my sample population, 79% experienced the phenomenon (Figure 1). There 
was a total of 19 respondents who did experience wear off and a total of 5 who did not. This 
corroborates the research done by Masters-Israilov & Robbins (2019) and Zidan et al. (2019). 
This study was also interested in documenting where in the treatment cycle wear off typically 


















Migraine Frequency on CGRP
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of every 12 weeks, leaves room for a period of vulnerability for those prone to wear off. The 
results indicated that patients in our sample population experienced wear off either within the 
tenth week or the eleventh week. Therefore, patients are vulnerable to rebound migraines 1-2 
weeks before their next treatment. For CM sufferers, this is a large gap and going without relief 
would proof detrimental to the patient’s health. During this time, bridge therapies such over the 
counter medications, and prophylactic medications-such as beta blockers, antihypertensives, 
anticonvulsants, antidepressant, etc.- are used to minimize the migraine attacks. CGRP 
antagonists taken monthly would be an effective addition to reduce the amount of rebound 
migraines that could occur during the wear off period or possibly completely eliminate the 
period. 
  The data showed that 11 respondents (Figure 5) experienced a positive response 
on a CGRP antagonist, while 12 respondents either had not started or did not experience a 
positive benefit. This was a surprising result as this research study’s hypothesis was to show that 
the combination of an anti-CGRP medication and onabotulinumtoxinA would further reduce 
migraine frequency and severity. The p value was 0.683, indicating that there was no statistical 
significance to the study. The observed values did not differ significantly from the expected 
values. Therefore, for this question, the null hypothesis was accepted. We concluded that 
majority patients on CGRP antagonists within the sample population, did not experience positive 
benefit. We were unable to demonstrate that the addition of CGRP-antagonists to current 
onabotulinumtoxinA patients would be significantly beneficial to their treatment.  
                    Among the patients that did experience positive benefit on a CGRP-antagonist, we 
looked to see if there was additional benefit in migraine frequency and severity reduction. For 
successful treatment of CM, patients should have greater or equal to 50% reduction in migraine 
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frequency - on average would be 8-9 migraine days - or at least 100 hours reduction in severity. 
Our results corroborated this statement as shown in figures 2 and 3. For those chronic migraine 
patients, onabotulinumtoxinA is an effective treatment option and many would agree that 
continuation is medically necessary. For successful treatment on a CGRP antagonist, chronic 
migraine patients should also have their migraine days decreased by 50%. The results indicated 
that majority of the sample population experienced over 50% additional reduction in migraine 
frequency and severity (Figures 6 &7). The study believed CGRP antagonists, could offer 
considerable improvements over existing drugs as they were specifically designed to act on the 
trigeminal ganglion, which plays a major role in primary headache pathophysiology.   
Conclusion. 
 Though this study was not able prove its hypothesis, we encourage further research 
on the topic. I would recommend that researchers collect data on patients who experience a 
positive benefit on onabotulinumtoxinA at the baseline but need additional reduction in total 
migraine days. An additional recommendation is that a larger population of chronic migraine 
patients who are on both onabotulinumtoxinA and a CGRP antagonist be recruited. This current 
study was able to show that there was some benefit with the addition of the CGRP antagonist to 
the treatment regimen. Future research should collect data multiple time to investigate if there is 
consistent significant improvement in patients. Through various studies discussed within this 
paper, there is proof that the two medications target different fibers in the brain and have 
differing mechanisms and, therefore can be used concurrently. It would be beneficial to 
clinicians that come up with multiple methods of combating the CGRP receptors that are 
released at a migraine attack.  
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 Additional research into the use of both onabotulinumtoxinA and CGRP 
antagonists is needed to show the efficacy and the medical necessity in treating chronic migraine. 
Further research is necessary to determine that CGRP antagonists are the answer to overcoming 
the wear off phenomenon that occurs towards the end of a standard 12-week cycle of 
onabotulinumtoxinA injections.  This research may help elucidate the mechanism of the action of 
both CGRP antagonists and onabotulinumtoxinA; and possibly implement methods that allow 
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1. How long have you been treated for chronic migraine? 
a. 0-5 years 
b. 6-10 years 
c.  11-15years 
d. 16 or more years 
2. Do you experience Botox wear off? 
a. Yes 
b. No 
3. If yes, when in treatment cycle do you usually experience wear off? 
a. Week 9 
b. Week 10 
c.  Week 11 
d. Unknown/Unsure 
4. What percentage would you say your migraine frequency decreased on Botox alone? 
a.  25% -50% 
b.  51% -75% 
c.  76% -100% 
5. What percentage would you say your migraine severity decreased on Botox alone? 
     a.   25% -50% 
     b.   51% -75% 
     c.   76% -100% 
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6. Do you experience positive benefit on a CGRP medication? (Aimovig, Emgality or 
Ajovy) 
    a. Yes 
    b. No 
7. What percentage would you say your frequency further decreased with the addition of a 
CGRP? 
   a. 25%-50% 
   b.     51%-75% 
               c.     76%-100% 
8. What percentage would you say your severity is further decreased with the addition of a 
CGRP? 
   a. 25%-50% 
   b.     51%-75% 
   c.     76%-100% 
 
 
 
 
 
 
 
 
 
 
  
